These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 17998874)
1. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Asano H; Lee CY; Fox-Talbot K; Koh CM; Erdinc MM; Marschner S; Keil S; Goodrich RP; Baldwin WM Transplantation; 2007 Nov; 84(9):1174-82. PubMed ID: 17998874 [TBL] [Abstract][Full Text] [Related]
2. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Qian Z; Lee CY; Murata K; Liu J; Fox-Talbot K; Wasowska BA; Baldwin WM Transplantation; 2006 Oct; 82(7):857-64. PubMed ID: 17038898 [TBL] [Abstract][Full Text] [Related]
3. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989 [TBL] [Abstract][Full Text] [Related]
4. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Fast LD; DiLeone G; Cardarelli G; Li J; Goodrich R Transfusion; 2006 Sep; 46(9):1553-60. PubMed ID: 16965583 [TBL] [Abstract][Full Text] [Related]
5. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Ambruso DR; Thurman G; Marschner S; Goodrich RP Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996 [TBL] [Abstract][Full Text] [Related]
6. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study. Picker SM; Steisel A; Gathof BS Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725 [TBL] [Abstract][Full Text] [Related]
7. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Cardo LJ; Rentas FJ; Ketchum L; Salata J; Harman R; Melvin W; Weina PJ; Mendez J; Reddy H; Goodrich R Vox Sang; 2006 Feb; 90(2):85-91. PubMed ID: 16430665 [TBL] [Abstract][Full Text] [Related]
8. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Marschner S; Fast LD; Baldwin WM; Slichter SJ; Goodrich RP Transfusion; 2010 Nov; 50(11):2489-98. PubMed ID: 20529002 [TBL] [Abstract][Full Text] [Related]
9. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Picker SM; Steisel A; Gathof BS Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255 [TBL] [Abstract][Full Text] [Related]
10. Functional inactivation of white blood cells by Mirasol treatment. Fast LD; Dileone G; Li J; Goodrich R Transfusion; 2006 Apr; 46(4):642-8. PubMed ID: 16584442 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990 [TBL] [Abstract][Full Text] [Related]
12. Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice. Jackman RP; Muench MO; Heitman JW; Inglis HC; Law JP; Marschner S; Goodrich RP; Norris PJ Transfusion; 2013 Nov; 53(11):2697-709. PubMed ID: 23451715 [TBL] [Abstract][Full Text] [Related]
13. A rat model of pregnancy-induced sensitization to transplants. Qian Z; Liu J; Fox-Talbot K; Wasowska BA; Baldwin WM Transplant Proc; 2005; 37(1):96-7. PubMed ID: 15808559 [TBL] [Abstract][Full Text] [Related]
14. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products. Keil SD; Saakadze N; Bowen R; Newman JL; Karatela S; Gordy P; Marschner S; Roback J; Hillyer CD Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832 [TBL] [Abstract][Full Text] [Related]
15. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. Ignatova AA; Karpova OV; Trakhtman PE; Rumiantsev SA; Panteleev MA Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Tonnetti L; Proctor MC; Reddy HL; Goodrich RP; Leiby DA Transfusion; 2010 May; 50(5):1019-27. PubMed ID: 20030791 [TBL] [Abstract][Full Text] [Related]
18. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model. Chi X; Zhi L; Vostal JG Transfusion; 2014 Jan; 54(1):74-85. PubMed ID: 23656563 [TBL] [Abstract][Full Text] [Related]
19. Prolonged cardiac allograft survival in presensitized rats after a high activity Yunnan-cobra venom factor therapy. Li R; Chen G; Guo H; Wang DW; Xie L; Wang SS; Wang WY; Xiong YL; Chen S Transplant Proc; 2006 Dec; 38(10):3263-5. PubMed ID: 17175243 [TBL] [Abstract][Full Text] [Related]
20. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Cardo LJ; Salata J; Mendez J; Reddy H; Goodrich R Transfus Apher Sci; 2007 Oct; 37(2):131-7. PubMed ID: 17950672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]